Veradermics Incorporated (MANE) Stock Forecast: StockMap's 2-Week Call

MANE stock forecast: StockMap's model makes no two-week call on Veradermics Incorporated after the Nov 19 close: its evidence is split, 4 reasons for and 11 against. Right in 1 of 5 two-week windows on MANE since Aug 21; by chance, a call on the same dates was right 63% of the time.

Veradermics Incorporated last closed at $124.39, -0.38% on the session.

Against the IVW growth benchmark the position is +1.95% over the forecast window.

Veradermics Incorporated's market cap is $5.25B as of November 19, 2026.

No call today: the model sees no clear direction · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is 1 (too close to call).

Where MANE sits: sized by market cap, coloured by the day's move.

The read is built from 15 underlying insights — 4 bullish and 11 bearish.

Agreement across those insights is 27%.

31 daily calls for MANE so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Veradermics Incorporated in the 25th percentile on return on equity, where 100 is best.

Veradermics Incorporated is classified under Health Care / Pharmaceuticals.

StockMap tracks Veradermics Incorporated as the 27th largest of the 153 companies it covers in the Pharmaceuticals industry, part of the Health Care sector.

Across that group the current two-week reads are 80 Moderate Underperform, 44 Neutral and 29 Strong Underperform.

On that composite Veradermics Incorporated ranks 12th of 153 in the group, against a group median of -0.36.

Other Health Care stocks

Research and education, not investment advice. The calls on this page come from StockMap's automated model, run on the close of November 19, 2026, and are the same for every reader. Calls are graded in public, misses included: how calls are graded, and the record. Who makes the calls and who pays for the site: Disclosures.

Veradermics Incorporated (MANE) — StockMap 2-week forecast & tracked accuracy